Oakbrook Investments LLC Grows Holdings in Illumina, Inc. (ILMN)

Share on StockTwits

Oakbrook Investments LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 82.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,925 shares of the life sciences company’s stock after acquiring an additional 4,475 shares during the quarter. Oakbrook Investments LLC’s holdings in Illumina were worth $3,084,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. Proficio Capital Partners LLC boosted its holdings in shares of Illumina by 61.7% in the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Colony Group LLC boosted its holdings in Illumina by 3.3% during the 4th quarter. Colony Group LLC now owns 1,172 shares of the life sciences company’s stock valued at $352,000 after acquiring an additional 37 shares during the period. Massmutual Trust Co. FSB ADV boosted its holdings in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 39 shares during the period. Whittier Trust Co. boosted its holdings in Illumina by 1.7% during the 4th quarter. Whittier Trust Co. now owns 2,697 shares of the life sciences company’s stock valued at $809,000 after acquiring an additional 44 shares during the period. Finally, Paradigm Asset Management Co. LLC boosted its holdings in Illumina by 8.3% during the 3rd quarter. Paradigm Asset Management Co. LLC now owns 650 shares of the life sciences company’s stock valued at $239,000 after acquiring an additional 50 shares during the period. 90.46% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on ILMN. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $355.00 price objective for the company in a report on Tuesday, April 2nd. OTR Global lowered Illumina to a “positive” rating in a research report on Tuesday, April 2nd. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Bank of America reaffirmed a “buy” rating and set a $355.00 target price on shares of Illumina in a research report on Wednesday, January 30th. Finally, Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price for the company. in a research report on Friday, January 25th. Three research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $346.97.

NASDAQ ILMN traded down $2.86 on Thursday, reaching $315.83. 28,245 shares of the stock traded hands, compared to its average volume of 961,204. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. The firm has a market cap of $46.62 billion, a PE ratio of 55.08, a price-to-earnings-growth ratio of 2.39 and a beta of 1.17. Illumina, Inc. has a 12 month low of $226.62 and a 12 month high of $372.61.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million for the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the firm earned $1.44 earnings per share. On average, research analysts expect that Illumina, Inc. will post 6.53 earnings per share for the current year.

In other news, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $280.11, for a total value of $34,733.64. Following the completion of the transaction, the senior vice president now directly owns 6,879 shares of the company’s stock, valued at approximately $1,926,876.69. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $317.01, for a total value of $1,046,133.00. Following the completion of the transaction, the director now directly owns 331,668 shares of the company’s stock, valued at $105,142,072.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,826 shares of company stock valued at $10,604,560. Corporate insiders own 0.54% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by Highlight Press and is the property of of Highlight Press. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://highlightpress.com/2019/04/18/oakbrook-investments-llc-grows-holdings-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: What is the NASDAQ?

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.